Daridorexant bulk supplier for pharma manufacturers

Daridorexant 25 mg, 50 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 25 mg, 50 mg

Reference Brands: Quviviq (USA/EU)

Category: Neurology

Daridorexant is a Neurology product available as Tablets in strengths 25 mg, 50 mg. It corresponds to the reference brand Quviviq (USA/EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Daridorexant? List it or send an offer →

Product Description:

Daridorexant is a dual orexin receptor antagonist. Orexin signalling promotes wakefulness, so blocking both OX1 and OX2 receptors reduces the wake drive rather than imposing sedation through GABA-A potentiation, which is how benzodiazepines and the z-drugs work. The practical consequence is a different morning profile — the half-life is tuned to cover the night without substantial residual effect the following day.

It is indicated for insomnia characterised by difficulty with sleep onset or sleep maintenance. Trials measured daytime functioning alongside sleep parameters, which is an unusual and relevant endpoint in this class. Contraindicated in narcolepsy, and exposure rises substantially with strong CYP3A4 inhibition.

Sourcing notes. Originator, on patent, no generic route, and scheduled as a controlled substance in several markets despite the absence of GABAergic dependence — the scheduling reflects class caution rather than observed abuse liability. Confirm both registration and scheduling in the destination market.

How Daridorexant is supplied today, and licensing ahead of patent expiry

Daridorexant is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Daridorexant, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Daridorexant supply →

Back to Listing

Frequently Asked Questions

Daridorexant is used for the treatment of insomnia in adults, helping to improve sleep onset, sleep maintenance, and overall sleep quality.

Daridorexant is a synthetic small-molecule dual orexin receptor antagonist (DORA) designed to block OX1 and OX2 receptors, thereby modulating the sleep-wake cycle.

The trade name of daridorexant is Quviviq.

Quviviq is developed and marketed by Idorsia Pharmaceuticals.

The complete generic name is daridorexant.

The brand name is Quviviq.

Daridorexant tablets are manufactured in regulatory-approved pharmaceutical facilities for the USA, EU, and UK markets, with production and quality standards managed by Idorsia Pharmaceuticals.

Quviviq (Daridorexant) is developed and sold by Idorsia. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.